VivoSeq
Metabolic & Endocrine

Obesity and Overweight

2

Pipeline Programs↗

2

Active Trials↗

2

Companies Involved↗

Obesity and Overweight is an early-stage landscape with 2 programs across 2 companies. The most active players are Pfizer, Eli Lilly. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

11/100

Mech. Concentration

100/100

Completion Rate

67/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

1 program

Phase 3Eli Lilly logo

Eli Lilly

2 programs

Phase 3

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 21

Tirzepatide

Eli Lilly

Phase 31

MET097

Pfizer

Approved
No programs

Analysis

Modality Breakdown

2programs
Small molecule150%
Peptide150%

Modality classified for 67% of 3 pipeline programs.

Analysis

Trial Status

5

clinical trials

Completed2 · 40%
Terminated1 · 20%
Recruiting1 · 20%
Enrolling by invitation1 · 20%

Clinical Trials

Trial Activity

Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV
Completed·UUniversity of Hawaii·Phase 2·NCT06935838·12 enrolled
Pilot Study on the Analysis of the Metabolic Phenotype in Individuals With Difficulties in Losing and Gaining Weight
Completed·UUniversity Hospital Schleswig-Holstein·N/A·NCT06860776·20 enrolled
Establishment of a Specific Metabolic Phenotyping for the Personalization of Obesity Therapy in Morbidly Obese Individuals
Terminated·UUniversity Hospital Schleswig-Holstein·N/A·NCT06874270·35 enrolled
Evaluating The Efficacy and Safety of MET097, a Fully-Biased, Ultra Long-Acting GLP-1RA, In People With Overweight or Obesity: A Phase 3, Multi-Center Randomized, Controlled Trial (VESPER-4)
Recruiting·Pfizer logoPfizer·Phase 3·NCT07311850·3,501 enrolled
The Efficacy and Safety of Herbal Medicine Treatment for Obese Patients With Spinal and Joint Pain: A Pragmatic Randomized Controlled Pilot Clinical Trial
Enrolling by invitation·JJaseng Medical Foundation·Preclinical·NCT06859697·40 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)